1-bromo-2-isopropoxy-4-nitrobenzene | 423165-35-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-2-isopropoxy-4-nitrobenzene
• 英文别名: Benzene,1-bromo-2-(1-methylethoxy)-4-nitro-；1-bromo-4-nitro-2-propan-2-yloxybenzene
• CAS: 423165-35-9
• 化学式: C₉H₁₀BrNO₃
• 分子量: 260.087
• InChiKey: XBBUHDSBHISUJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-bromo-2-isopropoxy-4-nitrobenzene 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 10% Pd/C 、 氢气 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 100.0 ℃ 、344.75 kPa 条件下， 反应 48.5h， 生成 2-[2-isopropoxy-4-(2-pyridylimino)aminophenyl]-5-[2-methyl-4-(2-pyridylimino)aminophenyl]furan methanesulfonate
  参考文献：
  名称：

  Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure–activity relationships

  摘要：

  Analogs of the lead antileishmanial bis-arylimidamide DB766 were prepared that possess unsymmetrical substitutions on the diphenylfuran linker, and an additional compound was synthesized that contains isopropoxy groups meta to the central furan. These agents all displayed nanomolar in vitro potency against intracellular Leishmania with selectivity indexes >100 compared to J774 macrophages. While the unsymmetrical analogs were toxic to mice when given ip at 30 mg/kg/day, the compound bearing the meta isopropoxy groups was well tolerated by mice and showed activity in a murine model of visceral leishmaniasis when administered ip at 30 mg/kg/day for five days. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.037
• 作为产物：
  描述：

  间硝基苯酚 在 溴 、 potassium carbonate 、 caesium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 1-bromo-2-isopropoxy-4-nitrobenzene
  参考文献：
  名称：

  Nitro-Substituted Hoveyda−Grubbs Ruthenium Carbenes:  Enhancement of Catalyst Activity through Electronic Activation

  摘要：

  The design, synthesis, stability, and catalytic activity of nitro-substituted Hoveyda-Grubbs metathesis catalysts are described. The highly active and stable meta- and para-substituted complexes are attractive from a practical point of view. These catalysts operate in very mild conditions and can be successfully applied in various types of metathesis [ring-closing metathesis, cross-metathesis (CM), and enyne metathesis]. Although the presence of a NO2 group leads to catalysts that are dramatically more active than both the second-generation Grubbs's catalyst and the phosphine-free Hoveyda's carbene, enhancement of reactivity is somewhat lower than that observed for a sterically activated Hoveyda-Grubbs catalyst. Attempts to combine two modes of activation, steric and electronic, result in severely decreasing a catalyst's stability. The present findings illustrate that different Ru catalysts turned out to be optimal for different applications. Whereas phosphine-free carbenes are catalysts of choice for CM of various electron-deficient substrates, they exhibit lower reactivity in the formation of tetrasubstituted double bonds. This demonstrates that no single catalyst outperforms all others in all possible applications.

  DOI：

  10.1021/ja048794v

文献信息

• [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011119704A1

  公开（公告）日：2011-09-29

  The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

  本发明涉及喹啉类似物、含有它们的药物组合物以及它们作为TRPV4拮抗剂的用途。
• [EN] AMINOTRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES<br/>[FR] AMINOTRIAZOLES POUR TRAITER DES MALADIES DÉMYÉLINISANTES
  申请人：VERTEX PHARMA

  公开号：WO2018106646A1

  公开（公告）日：2018-06-14

  The invention relates to triazole compounds of formula (I') or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: wherein A is selected from the group consisting of (i), (ii), (iii), (iv), (v), and (vi) The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

  该发明涉及式(I')的三唑化合物或其药学上可接受的盐，用作脱髓鞘疾病的调节剂：其中A选自(i)、(ii)、(iii)、(iv)、(v)和(vi)所述的组。该发明还提供包括该发明化合物的药学上可接受的组合物，以及在治疗各种脱髓鞘和神经退行性疾病，包括多发性硬化症中使用这些组合物和配套工具的方法。
• [EN] ANTI-FUNGAL TREATMENT<br/>[FR] TRAITEMENT ANTIFONGIQUE
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2018045106A1

  公开（公告）日：2018-03-08

  Provided are compounds, methods, and pharmaceutical compositions useful for treatment of fungal infections, e.g., aspergillosis, candidiasis, cryptococcosis, histoplasmosis, and the like. For example, the pharmaceutical composition may include a pharmaceutically acceptable carrier or excipient, and a compound represented by Ar— C(=NR1)NR2— A---X— Y— Het2 and pharmaceutically acceptable salts thereof. Ar may be an optionally substituted aryl or nitrogen- containing heteroaryl. R1 and R2 may independently be H, optionally substituted C1-C6 aikyi, or optionally substituted C3-C6 cyeloalkyi. A may be a bond or an optionally substituted linking moiety comprising 1, 2, or 3 rings. Each ring in the optionally substituted linking moiety may independently be one of: aryl, cyeloalkyi, heterocycloalkyl, and heteroaryl. X may be O, S, amide, or a bond. Y may be optionally substituted C1-C10 alkyi or optionally substituted C2-C10 alkenyl. Het2 may be an optionally substituted five-membered nitrogen-containing heteroaromatic ring comprising 1, 2, or 3 ring heteroatoms.

  提供了用于治疗真菌感染的化合物、方法和药物组合物，例如曲霉病、念珠菌感染、隐球菌病、组织胞浆菌病等。例如，药物组合物可以包括药用可接受载体或赋形剂，以及由Ar—C(=NR1)NR2—A---X—Y—Het2表示的化合物及其药用可接受的盐。Ar可以是可选择取代的芳基或含氮的杂环芳基。R1和R2可以独立地是H、可选择取代的C1-C6烷基或可选择取代的C3-C6环烷基。A可以是键或包含1、2或3个环的可选择取代的连接基。可选择取代的连接基中的每个环可以独立地是以下之一：芳基、环烷基、杂环烷基和杂芳基。X可以是O、S、酰胺或键。Y可以是可选择取代的C1-C10烷基或可选择取代的C2-C10烯基。Het2可以是可选择取代的含五个成员的含氮杂芳环，其中包括1、2或3个环杂原子。
• [EN] ANTI-PARASITIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIPARASITAIRES
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2018045104A1

  公开（公告）日：2018-03-08

  Provided are compounds, methods, and pharmaceutical compositions useful for treatment of parasites, e.g., Leishmania. For example, the compound may he represented by Ar—C(=NR1)NR2—A—X—Y—Het2, and pharmaceutically acceptable salts thereof. Ar may be an optionally substituted, aryl or nitrogen-containing heteroaryl. R1 and R2 may independently represent H, optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl. A may be a bond or an optionally substituted linking moiety comprising 1, 2, or 3 rings. Each ring in the optionally substituted linking moiety may independently be one of: aryl, cycloalkyl, heterocycloalkyl, and heteroaryl. X may be O, S, amide, or a bond. Y may be optionally substituted C1-C14 alkyl or optionally substituted C2-C14 alkenyl. Het2 may be an optionally substituted five-membered nitrogen-containing heteroaromatic ring comprising 1, 2, or 3 ring heteroatoms.

  提供了一些化合物、方法和药物组合物，用于治疗寄生虫，例如利什曼虫。例如，该化合物可以表示为Ar—C(=NR1)NR2—A—X—Y—Het2，及其药学上可接受的盐。Ar可以是可选择取代的芳基或含氮的杂芳基。R1和R2可以独立表示H、可选择取代的C1-C6烷基或可选择取代的C3-C6环烷基。A可以是一个键或一个可选择取代的连接基，包括1、2或3个环。可选择取代的连接基中的每个环可以独立地是以下之一：芳基、环烷基、杂环烷基和杂芳基。X可以是O、S、酰胺或一个键。Y可以是可选择取代的C1-C14烷基或可选择取代的C2-C14烯基。Het2可以是一个可选择取代的含有5个成员的含氮杂芳环，包括1、2或3个环杂原子。
• Synthesis and Antiprotozoal Activity of Dicationic <i>m</i>-Terphenyl and 1,3-Dipyridylbenzene Derivatives
  作者：Donald A. Patrick、Mohamed A. Ismail、Reem K. Arafa、Tanja Wenzler、Xiaohua Zhu、Trupti Pandharkar、Susan Kilgore Jones、Karl A. Werbovetz、Reto Brun、David W. Boykin、Richard R. Tidwell

  DOI：10.1021/jm400508e

  日期：2013.7.11

  Bis-pyridylimidamide derivative 31 was 25 times more potent than benznidazole against T. cruzi and slightly more potent than amphotericin B against L. amazonensis. Terphenyldiamidine 1 and dipyridylbenzene analogues 23 and 25 each cured 4/4 mice infected with T. b. rhodesiense STIB900 with four daily 5 mg/kg intraperitoneal doses, as well as with single doses of ≤10 mg/kg. Derivatives 5 and 28 (prodrugs

  4,4“-Diamidino-米-三联苯（1制备并在体外测定对抗T）和36类似物rypanosoma布氏罗得西亚，克氏锥虫，疟原虫和利什曼原虫亚马孙。23种化合物对T. b具有很高的活性。罗得西亚或恶性疟原虫。最值得注意的是脒1，10，和11与IC 50 4nM的反对的布氏锥虫 罗得香和二甲基四氢嘧啶类似物4和9（IC 50）对恶性疟原虫的值≤3 nM 。双吡啶基酰亚胺酰胺衍生物31对T的效力是苯并咪唑的25倍。克鲁氏菌对亚马逊乳酸杆菌的杀伤力比两性霉素B强。三联苯二胺1和二吡啶基苯类似物23和25分别治愈了感染T.b的4/4小鼠。罗得西亚STIB900具有四个每日5mg / kg的腹膜内剂量，以及与单次剂量的≤10毫克/公斤。衍生物5和28（前药1和25）每只治愈3/4只小鼠，每天四次口服25 mg / kg口服剂量。